IN8bio, Inc. — Form 8-K Summary
Reporting date: December 16, 2021. The filing was submitted under Item 8.01 to report an update from the ongoing Phase 1 clinical trial of INB-100, an investigational therapy. IN8bio’s common stock trades on the Nasdaq Global Select Market under the symbol INAB.
Financial and Operating Metrics
The filing text does not provide revenue, net income, cash flow, margins, debt, liquidity, or other financial metrics. It also does not provide clinical-trial data or the substance of the referenced press release.
Material Changes Versus Prior Period
The filing reports a clinical-trial update but does not provide sufficient information to assess changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
- The filing references an update from the ongoing Phase 1 clinical trial of INB-100.
- No guidance, forecast, management commentary, risk disclosures, contingencies, safety findings, efficacy results, or milestone details are included in the supplied filing text.
- The referenced December 16, 2021 press release was filed as Exhibit 99.1, but its contents are not included in the source provided.
Facts Investors Should Verify
- Review Exhibit 99.1 for the complete INB-100 clinical-trial update.
- Verify the reported patient population, safety and efficacy findings, dosing information, and trial timeline.
- Check subsequent filings for clinical-development progress, financing activity, cash runway, and updated risk factors.